More than a million individuals living with heart disease in the UK are set to gain access to weight-loss injections on the NHS, marking a significant evolution in the treatment of cardiovascular conditions. Under new guidance from the National Institute for Health and Care Excellence (NICE), patients who have previously suffered a heart attack or stroke will be eligible for a weekly injection of Wegovy, a drug containing the active ingredient semaglutide. This intervention aims to significantly reduce their risk of experiencing another life-threatening cardiovascular event.

This innovative treatment will be administered in conjunction with established therapies such as cholesterol-lowering statins, blood pressure medication, and comprehensive diet and lifestyle counseling. The decision by NICE is particularly noteworthy as it represents the first time Wegovy has been approved in the UK specifically for the prevention of further heart problems, rather than solely for its established uses in managing obesity and diabetes. Growing scientific evidence indicates that semaglutide acts directly on the heart and blood vessels, offering benefits beyond simple weight reduction, thereby lowering the risk of future cardiovascular events.

The change in guidance is supported by robust findings from the landmark SELECT trial, which involved over 17,000 patients diagnosed with cardiovascular disease. Participants in this study received weekly injections of semaglutide in addition to their standard care. The results demonstrated that those on the drug were 20 percent less likely to suffer a major heart event, such as a heart attack or stroke, compared to those given a placebo. Crucially, the benefits of the drug were observed early in the trial, prior to significant weight loss, suggesting a direct cardiovascular protective effect independent of its impact on body weight.

Heart disease continues to be a leading cause of mortality in the UK, accounting for over 460 deaths daily, or roughly one death every three minutes. Annually, more than 200,000 people experience a heart attack or stroke. Approximately eight million individuals in the UK live with cardiovascular disease, with an estimated 1.2 million meeting the new eligibility criteria due to a body mass index (BMI) above 27. Patients with conditions like peripheral arterial disease, or those with a history of heart attack or stroke, face a substantially elevated risk of recurrent, potentially fatal events.

NICE's independent committee concluded that semaglutide offers a meaningful clinical benefit for these high-risk patients and represents a cost-effective allocation of NHS resources. Helen Knight, director of medicines evaluation at NICE, highlighted that the decision provides